These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 27143662)
1. Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial. Arenas-Pinto A; Stöhr W; Jäger HR; Haddow L; Clarke A; Johnson M; Chen F; Winston A; Godi C; Thust S; Trombin R; Cairns J; Solanky BS; Golay X; Paton NI; Clin Infect Dis; 2016 Jul; 63(2):257-64. PubMed ID: 27143662 [TBL] [Abstract][Full Text] [Related]
2. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803 [TBL] [Abstract][Full Text] [Related]
3. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. Pérez-Valero I; González-Baeza A; Estébanez M; Montes-Ramírez ML; Bayón C; Pulido F; Bernardino JI; Zamora FX; Monge S; Gaya F; Lagarde M; Rubio R; Hernando A; Arnalich F; Arribas JR PLoS One; 2013; 8(7):e69493. PubMed ID: 23936029 [TBL] [Abstract][Full Text] [Related]
4. Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial. Arenas-Pinto A; Stöhr W; Khoo S; Clarke A; Beeching N; Warwick Z; Lee V; Else L; Wiggins R; Ferns B; Nastouli E; Dunn D; Lacey CJ; Paton NI; Antivir Ther; 2020; 25(1):55-59. PubMed ID: 32202510 [TBL] [Abstract][Full Text] [Related]
5. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Paton NI; Stöhr W; Arenas-Pinto A; Fisher M; Williams I; Johnson M; Orkin C; Chen F; Lee V; Winston A; Gompels M; Fox J; Scott K; Dunn DT; Lancet HIV; 2015 Oct; 2(10):e417-26. PubMed ID: 26423649 [TBL] [Abstract][Full Text] [Related]
6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
7. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. Negredo E; Estrada V; Domingo P; Gutiérrez MD; Mateo GM; Puig J; Bonjoch A; Ornelas A; Echeverría P; Estany C; Toro J; Clotet B J Antimicrob Chemother; 2017 Mar; 72(3):844-849. PubMed ID: 27999056 [TBL] [Abstract][Full Text] [Related]
8. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S; Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747 [TBL] [Abstract][Full Text] [Related]
9. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K; Lancet HIV; 2016 Aug; 3(8):e343-e350. PubMed ID: 27470026 [TBL] [Abstract][Full Text] [Related]
10. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA; Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068 [TBL] [Abstract][Full Text] [Related]
11. Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor Monotherapy. Haddow LJ; Godi C; Sokolska M; Cardoso MJ; Oliver R; Winston A; Stöhr W; Clarke A; Chen F; Williams IG; Johnson M; Paton N; Arenas-Pinto A; Golay X; Jäger HR Clin Infect Dis; 2019 Mar; 68(6):1031-1040. PubMed ID: 30084882 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. Arribas JR; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB HIV Med; 2016 May; 17(5):358-67. PubMed ID: 26709605 [TBL] [Abstract][Full Text] [Related]
14. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551 [TBL] [Abstract][Full Text] [Related]
15. Ritonavir-boosted lopinavir as maintenance monotherapy in HIV-infected patients who achieved viral suppression during a second-line protease inhibitor-based regimen: a pilot randomized trial (BIDI-MONO). Siripassorn K; Chottanapund S; Prasithsirikul W; Manosuthi W J Int Assoc Provid AIDS Care; 2014; 13(4):353-60. PubMed ID: 25513033 [TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial. Oddershede L; Walker S; Stöhr W; Dunn DT; Arenas-Pinto A; Paton NI; Sculpher M; Pharmacoeconomics; 2016 Aug; 34(8):795-804. PubMed ID: 26966125 [TBL] [Abstract][Full Text] [Related]
17. Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy. Reina E; San Miguel R; Larrea N; Garcia P; Napal V Int J Clin Pharm; 2012 Dec; 34(6):911-6. PubMed ID: 23007692 [TBL] [Abstract][Full Text] [Related]
18. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM; AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288 [TBL] [Abstract][Full Text] [Related]
19. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. Galli L; Spagnuolo V; Bigoloni A; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Borderi M; Gibellini D; Caramatti G; Lazzarin A; Castagna A; J Antimicrob Chemother; 2016 Jun; 71(6):1637-42. PubMed ID: 26945711 [TBL] [Abstract][Full Text] [Related]
20. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy. Valantin MA; Kolta S; Flandre P; Algarte Genin M; Meynard JL; Ponscarme D; Slama L; Cuzin L; de Kerviler E; Inaoui R; Katlama C HIV Med; 2012 Sep; 13(8):505-15. PubMed ID: 22416798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]